Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
56,260,480
-
Total 13F shares
-
20,143,303
-
Share change
-
+8,350,640
-
Total reported value
-
$67,479,982
-
Put/Call ratio
-
258%
-
Price per share
-
$3.35
-
Number of holders
-
67
-
Value change
-
+$28,429,772
-
Number of buys
-
46
-
Number of sells
-
9
Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) as of Q4 2025
As of 31 Dec 2025,
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,143,303 shares.
The largest 10 holders included
Nantahala Capital Management, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, Woodline Partners LP, MILLENNIUM MANAGEMENT LLC, IEQ CAPITAL, LLC, Almitas Capital LLC, SUPERSTRING CAPITAL MANAGEMENT LP, STEMPOINT CAPITAL LP, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
67
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.